Newsletter · · Ashutosh Agarwal

Trump Threatens 100% Tariff on Generic Drugmakers as Pricing Fights Widen - Drug Pricing & IRA Round 2 - Week of July 21–27, 2026

President Trump's threatened 100% tariff on generic drugmakers led a week that also brought a transparent PBM founder's look inside drug-benefit economics, a Senate insulin-cap hearing, and a quiet Medicare GLP-1 access expansion, for the week of July 21 to 27, 2026.

Drug Pricing & IRA Round 2

Week of July 21–27, 2026: Trump Threatens 100% Tariff on Generic Drugmakers as Pricing Fights Widen

TL;DR

  • The biggest development of the week was not about the negotiation program at all, it was a tariff threat aimed squarely at the cheapest corner of the drug world. On a July 22 Bloomberg Daybreak, reporter John Tucker relayed that President Trump, in a social-media post, told generic drug manufacturers they have two years to move production to the United States or face a 100% import duty starting in August of next year, then doubling to 200% the following year. Generics are more than 90% of all US prescriptions, and they run on razor-thin margins, so this is a shortage-and-price-hike risk, not a pricing-power story. (Bloomberg Daybreak: US Edition)
  • A rare on-the-record look inside the middleman business came from Jake Frenz, founder and CEO of the transparent pharmacy-benefit manager SmithRx, who put numbers on how big the drug benefit has become and how the money hides. Drug spending has gone from "single digits" of the healthcare bill a decade ago to "35% to 40%" today (over 50% at some employers), and on generic drugs the industry still marks off "90% or even above" a made-up sticker price. (The Benefits Playbook)
  • Washington is moving on insulin again. On a July 21 Diabetes Connections news roundup, host Stacey Sims reported that the Senate has scheduled a hearing this week on the Insulin Act of 2026, which would cap patient insulin costs at $35, against a production cost Yale researchers estimate at "about $2 to $4 to produce a vial." The same episode flagged a quieter but important payer change: since July 1, eligible Medicare Part D patients have an easier path to weight-loss drugs (Wegovy, Zepbound, and Novo's Foundeo) through a new "Medicare GLP-1 bridge program." (Diabetes Connections)
  • The AbbVie playbook got named and shamed on a July 23 Mostly Economics episode with IP lawyer Tahir Amin, who walked through how Humira's patent wall (AbbVie's own CEO admitted to 136 patents in 2019 Senate testimony) pushed off biosimilar competition to 2023 and let the drug earn "$114 billion in revenue just in that seven years" while its price rose "almost 470%." Useful history for anyone modeling how hard branded pharma fights to protect a franchise. (Mostly Economics)

What's new

1. A 100% tariff threat lands on generic drugmakers, the opposite of a pricing-power story

Rank this first, because it's the one genuinely new, market-moving item of the week, and it hits a part of the industry that has almost no cushion to absorb it.

Here's the plain-English version. Most of the drug-pricing fights this letter tracks are about brand-name medicines, the expensive, patent-protected blockbusters. This threat is aimed at the other end: generics, the cheap copies that appear once patents expire and that make up the overwhelming majority of prescriptions Americans actually fill. On the July 22 Bloomberg Daybreak: US Edition, Bloomberg's John Tucker summarized a Trump social-media post this way:

"Generic drug manufacturers are going to have two years to move production to the US or face a 100% import duty. This would all start in August of next year. The tariffs would then double to 200% the following year."

Tucker went straight to the catch: "It's unclear how forcing companies to make more medicines in the US will help bring prices down, given the lower costs of labor and manufacturing in established locations like India." He added that "the planned tariffs would raise costs for manufacturers who already operate on pretty thin margins, risking higher prices and potential shortages for the generic treatments that account for more than 90% of US prescriptions." (Bloomberg Daybreak: US Edition)

Source note: this is a journalist relaying a presidential social-media post, not an operator or a formal rule, so treat it as a real signal of intent with the usual caveat that Trump tariff threats have a history of being softened, delayed, or negotiated away. But the direction matters. Every other pricing lever in this letter squeezes brand-name margins; this one threatens to raise the cost of the cheapest drugs and strain a fragile, low-margin, heavily-offshore supply chain (India in particular). For a book, the read is less "who has pricing power" and more "who has US manufacturing, and who is exposed to a generics supply shock." Note also that this generic-tariff threat sits alongside the separate, brand-name "Most Favored Nation" story that dominated last week: they are two different fronts, and this week the new news was on generics.

2. Inside the middleman machine: a transparent-PBM founder puts numbers on the black box

The most number-dense operator interview of the week was a July 23 episode of The Benefits Playbook with Jake Frenz, founder and CEO of SmithRx, a "transparent" pharmacy-benefit manager. Quick definition: a pharmacy-benefit manager (PBM) is the company employers and insurers hire to run their drug coverage, it decides which drugs are covered and negotiates the prices. The three giants (CVS Caremark, Express Scripts, and Optum) dominate the business; SmithRx is a small challenger that pitches itself on transparency, so read Frenz as an insider who is also selling against the incumbents.

His numbers are the useful part:

  • The drug benefit has exploded as a share of the bill. "That spend as a percentage of the healthcare spend went from the single digits to when I started Smith 10 years ago, it was 15%. And now it's even 35% to 40% of the healthcare spend today." He and the host agreed some employers are already past 50%, and Frenz cited employers staring at a "14% drug spend increase they saw last year." (The Benefits Playbook)
  • The generic markup is surreal. Under the traditional model, drugs are priced off a made-up sticker number (the "average wholesale price"), and "for generics today, that's 90% or even above" off. As Frenz put it: "where else in life do you get 90% off of anything?" The size of the discount tells you the sticker price was fiction to begin with. (The Benefits Playbook)
  • Rebates are where the money hides, and he'd abolish them. Asked point-blank whether rebates should exist, Frenz said: "Probably not. I don't think they should." He described the classic tell for employers, the fat quarterly "rebate check" (his example: "$350,000 every quarter") that makes a plan feel like it's winning while more money quietly flows out the door up front. (The Benefits Playbook)
  • The pressure is building from every direction. "Every state has controls and rules... Today the FTC, DOJ, state to state" are all circling PBMs, though Frenz was candid that he hasn't "seen any legislation or action... to totally swing the pendulum." For scale, he said SmithRx now has "1.5 million members today across 5,000 self-insured companies." (The Benefits Playbook)

Why it matters for numbers: this is the plumbing that sets the real economics for both drugmakers and the PBM-owned insurers. Frenz is talking his book, a challenger wants the incumbents' spread shrunk, but the fact that a founder-CEO will say "rebates shouldn't exist" out loud, and that regulators are circling, is exactly the kind of narrative pressure that slowly re-rates a regulated profit pool.

3. Congress reaches for the insulin cap again, and Medicare quietly opens the GLP-1 door

On a July 21 Diabetes Connections news roundup, host Stacey Sims (a patient-advocacy journalist, not an industry insider) flagged two policy items worth a book's attention.

First, insulin. "The Senate takes up the federal cap on insulin prices. A hearing on the Insulin Act of 2026 is scheduled for this week." The cap under discussion "would be set at $35, much like a lot of states have set caps on their state insurance plans," against a production cost that "the Yale School of Medicine has estimated... can cost about $2 to $4 to produce a vial of insulin." The bill "is awaiting action in the Senate Health Committee before it can move forward," so this is a hearing, not a law, but it keeps insulin pricing on the front burner for Eli Lilly, Novo Nordisk, and Sanofi. (Diabetes Connections)

Second, and easier to miss, a Medicare coverage expansion for weight-loss drugs. Sims: "starting on July 1st, eligible Medicare Part D patients have a much easier path to accessing FDA-approved weight management medications, including Wegovy, Zepbound, and Foundeo. This is a Medicare GLP-1 bridge program." In plain terms, Medicare is opening a door it had largely kept shut, which points to more volume for the GLP-1 makers even as the same drugs are the most obvious future price-negotiation and MFN targets. Volume up, price under pressure, that tension is the whole GLP-1 story in one line. (Diabetes Connections)

The same episode noted Roche walked away from a GLP-1 for type 1 diabetes (acmopatide) on "a business decision" despite good study results, while Eli Lilly keeps running a larger Phase 3 trial of tirzepatide in type 1, a small reminder of how selective even the deep-pocketed players are getting about where GLP-1 dollars go. (Diabetes Connections)

4. The Humira patent-wall autopsy, a reminder of how hard a franchise fights

For structural background rather than fresh news, a July 23 Mostly Economics conversation with Tahir Amin, an intellectual-property lawyer and co-founder of the drug-access advocacy group I-MAK, is worth filing away. Amin is an advocate, not a neutral analyst, his whole thesis is that patents are abused, so weight it accordingly. But his AbbVie/Humira case study is concrete and checkable:

Amin noted that AbbVie's own CEO, testifying to a Senate committee in 2019, "admitted that they had 136 granted patents around this particular drug" (Amin's group counts even more, "over 300 patent applications, nearly 200 granted patents"). Humira's core patent was set to expire in 2016, but the patent thicket pushed real biosimilar competition to 2023: "they bought themselves an extra seven years... which then allowed them to make $114 billion in revenue just in that seven years. And the price went up... almost 470%." (Mostly Economics)

He put the same lens on other categories: the hepatitis C cure that arrived in 2013 at "up to 84,000 for a three-course treatment" and had to be rationed by state budgets, and the GLP-1s, where "studies... shown that actually [they] cost a fraction to make of what they're charging." (Mostly Economics)

Why it matters: it's a clean illustration of the single most important defensive habit in this sector, branded pharma will spend enormous effort to stretch a franchise past its "natural" patent life. That instinct is exactly what runs headlong into IRA negotiation timelines and the pill-penalty debate, and it's why the policy fight is so bitter.

The debate

The core argument is the same one this letter has been running, but this week's news shifts the emphasis from brand-name margins to the generic supply chain, a genuinely different risk.

"It's a bounded, buy-your-way-out headwind, and the industry can adapt." The bull case says the branded MFN drama is largely settled (last week a CMS official confirmed deals with all 17 big manufacturers), and this week's generic-tariff threat is a classic Trump opening bid: two years of runway, an obvious off-ramp (build US capacity), and a strong chance it gets negotiated down. Medicare quietly opening the door to GLP-1s (the July 1 "bridge program") is a reminder that policy also creates volume, not just price cuts. Companies with cash and US manufacturing can absorb and even benefit. (Bloomberg Daybreak: US Edition; Diabetes Connections)

"It's a squeeze from both ends at once, and now the cheap drugs are in the crosshairs too." The bear reading is that the pressure is no longer just on blockbuster brand pricing. A 100% (rising to 200%) tariff on generics threatens the one part of the system that actually keeps costs down for patients, and, as Bloomberg's own reporter noted, it's "unclear how" it lowers prices; the likelier outcomes are "higher prices and potential shortages." Layer that on top of the PBM squeeze (Jake Frenz's "90% off" generics and hidden rebates), the insulin cap bill, and the patent-thicket history that shows how much of branded revenue depends on keeping competition out, and you get margin pressure on brands and cost/shortage risk on generics at the same time. (Bloomberg Daybreak: US Edition; The Benefits Playbook; Mostly Economics)

The swing factor this week is simple: does the generic tariff become real, and does anyone actually relocate manufacturing? Building sterile-injectable and API capacity in the US takes years and costs money the generic business doesn't have. Until there's a formal rule (not a social-media post) and a company that says "we're moving," this is a threat to price into the generics/supply chain, not a settled cost.

Stocks in play

No podcast this week attached a franchise-level revenue-at-risk number to a tracked name, so what follows is only what the week's episodes actually implied.

Eli Lilly (LLY) and Novo Nordisk (NVO), the week's most-discussed names, mostly via their legal fight, plus the Medicare volume angle.

  • Bull (LLY): Jim Cramer, on the July 21 Squawk on the Street, stayed "incredibly bullish" on Lilly and called Novo's new lawsuit "not a big deal," arguing Lilly's efficacy ad is lifted "right out of New England Journal of Medicine" (the May 11, 2025 paper) and that "in the end, it's about infrastructure. Lilly's got better infrastructure." He framed weakness (Lilly down ~7% that day) as a buying opportunity. Note: Cramer is a media pundit talking his trust's position, not an operator. (Squawk on the Street)
  • Bull (both): the July 1 Medicare GLP-1 "bridge program" points to more covered volume for Wegovy, Zepbound, and Novo's Foundeo. (Diabetes Connections)
  • Bear: these are the exact "high volume, high utilization" drugs that sit at the center of every pricing lever, MFN, future negotiation, and now a Medicare population getting easier access at a moment when the government is hunting for savings. Cramer himself hit the tension: "Medicare gives you this thing for very little money... a lot of the diseases that are being targeted are diseases that other companies have made a lot of money on, and they're not going to make as much money." And the NVO-vs-LLY comparative-advertising suit is a sign of how bare-knuckle the GLP-1 share fight has become. (Squawk on the Street)
  • Next to watch: the outcome of the Novo/Lilly ad lawsuit; any formal Medicare rule text on the GLP-1 bridge program; whether Ozempic/Wegovy or a tirzepatide land on a future selected-drug list.

AbbVie (ABBV), background only, via the Humira patent-thicket case study.

  • Bull: AbbVie has already navigated the Humira cliff and diversified into Skyrizi and Rinvoq; the patent history shows how effectively it defends and extends a franchise.
  • Bear: the same episode is a reminder that AbbVie's peak Humira economics rested on keeping biosimilars out until 2023 and pushing price up "almost 470%," precisely the behavior that IRA negotiation and the pill-penalty debate are designed to curb. (Mostly Economics)
  • Next to watch: post-Humira franchise durability against the negotiation clock (no fresh podcast commentary this week).

JNJ, PFE, MRK, BMY, AZN, no company-specific podcast commentary this week. The only read-through is sector-level: all carry blockbusters exposed to negotiation and MFN, and, new this week, several also have generic/biosimilar or supply-chain exposure that the tariff threat touches. Franchise-level numbers will have to come from filings and Street models rather than this week's podcasts.

Generic makers (see Read-throughs), the tariff threat is squarely their problem; details below.

Read-throughs

Generic / biosimilar makers (incl. TEVA, and Indian exporters like Sun, Dr. Reddy's, Cipla). This is the week's sharpest new read. A 100% import duty rising to 200%, aimed at manufacturers who "already operate on pretty thin margins," with production concentrated in India, is a direct threat to the low-cost generic model, and the likely result, per Bloomberg's reporter, is "higher prices and potential shortages," not lower prices. Names with meaningful US manufacturing footprints are relatively better positioned; pure importers are most exposed. Watch for any company that responds by announcing US capacity, that's the tell that the threat is being taken literally. (Bloomberg Daybreak: US Edition)

PBMs / managed care (CVS, CI, UNH). Jake Frenz's interview is more narrative pressure on the same profit pool this letter has been flagging: drug spend now "35% to 40%" of the healthcare bill, generic markups of "90% or even above," a founder-CEO saying rebates probably "shouldn't exist," and regulators "state to state" plus the FTC and DOJ circling. Frenz is a challenger talking his book, and he admits nothing has yet "swung the pendulum," so this is pressure, not a rule. But narrative pressure is what slowly re-rates a regulated spread. Interesting aside for these names: a generic tariff that raises acquisition costs would also scramble the PBMs' generic economics, not just the manufacturers'. (The Benefits Playbook)

Insulin makers (LLY, NVO, Sanofi). The Insulin Act of 2026 Senate hearing keeps a $35 cap in play against a $2–$4 production cost, years into a trend where the big three have already cut US list prices under pressure. A federal cap is a headline risk more than a fresh earnings shock for names that have largely repriced insulin already, but it signals Congress still sees insulin as the easiest political win in drug pricing. (Diabetes Connections)

Ex-US launch strategy and small-mol vs. biologic mix. The one operator voice touching the negotiation/MFN framework directly was Matt Winton, Chief Commercial and Business Officer at CervoMed, on a July 20 Business of Biotech. He described how "new laws," "most favored nations," and IRA negotiation are rewriting the launch playbook: "there was always the launch playbook, you launch in these countries first... that may change things." He said pricing decisions have been "elevated up to the board" because a wrong call can land a company "on the front page of The New York Times or in front of Congress," and, a subtle point for deal-watchers, a small biotech's pricing choices can affect "a large pharma's willingness to acquire you or to partner with you," because a low overseas price can drag on the acquirer's US and Europe profit centers. Translation for a book: MFN reference pricing doesn't just hit today's blockbusters, it changes where and how new drugs launch, and even how M&A gets priced. (Business Of Biotech)

What changed vs. last week

Last week (July 14–20) was about two things: a CMS Deputy Administrator confirming, on the record, "deals with all of the 17 major drug manufacturers" on brand-name MFN pricing, and a number-heavy PBM/gross-to-net story ("$41 of every $100" on generics).

What genuinely moved this week:

  • A new tariff front opened, on generics, not brands. The MFN story is about brand-name price cuts; this week's news was a threatened 100% (then 200%) import duty on generic manufacturers who don't move production to the US within two years, starting August of next year. That's a different risk (supply shortages and higher costs on cheap drugs) hitting a different set of companies (generic and biosimilar makers, especially Indian exporters). (Bloomberg Daybreak: US Edition)
  • Insulin came back onto the calendar with a scheduled Senate hearing on the Insulin Act of 2026 and its $35 cap. (Diabetes Connections)
  • A concrete Medicare volume change surfaced, the July 1 "GLP-1 bridge program" easing Part D access to weight-loss drugs, which is a rare positive-for-volume policy item amid a lot of price-cut news. (Diabetes Connections)
  • The PBM and patent-abuse narratives got fresh, quotable airings (SmithRx's Frenz on the "black box"; Tahir Amin on Humira's $114B/470% patent wall). New color, same direction of travel. (The Benefits Playbook; Mostly Economics)